
Growth stocks, particularly those in the biotech sector, can be lucrative long-term investments. The biotech sector often develops cutting-edge treatments (like gene therapy, immuno-oncology, and obesity drugs) that have the potential to redefine the healthcare industry. Shares of companies in the clinical stage can skyrocket in a short period of time following the success of a clinical trial or FDA approval.
However, these stocks also carry high risk, as their performance is heavily reliant on innovation, clinical trial success, and regulatory approval. Here are two “Strong Buy”-rated biotech growth stocks with potential upside of more than 200% that Wall Street believes are worth the risk.